HER2-negative Breast Cancer
145
54
72
35
Key Insights
Highlights
Success Rate
66% trial completion
Published Results
26 trials with published results (18%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.4%
18 terminated out of 145 trials
66.0%
-20.5% vs benchmark
10%
14 trials in Phase 3/4
74%
26 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 35 completed trials
Clinical Trials (145)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PRE-ISPY Phase I/II Oncology Platform Program
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer